MIST

Business Context and Reporting Period

Company: Milestone Pharmaceuticals Inc. (MIST)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Milestone is a biopharmaceutical company focused on cardiovascular medicines. Its primary asset is CARDAMYST (etripamil) nasal spray, which received FDA approval on December 12, 2025, for the treatment of paroxysmal supraventricular tachycardia (PSVT). The company is transitioning from a pure R&D model to commercialization, with a sales force of approximately 60 representatives targeting the U.S. market. It is also developing etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR).

Key Financial Metrics

Note: Revenue consists entirely of a $1.5 million milestone payment from a licensing partner. The company has not yet generated product sales revenue.

Material Changes vs. Prior Period

• Revenue Recognition: The company recorded $1.5 million in license revenue in 2025, compared to zero in 2024, triggered by the FDA approval of CARDAMYST.
• Commercial Expenses: Increased by 157.2% (from $11.0 million to $28.3 million) due to the build-out of the commercial infrastructure and sales force for the U.S. launch.
• Net Loss: Increased by 51.9% to $63.1 million, driven by higher commercial and R&D expenses, partially offset by interest income.
• Liquidity Position: Cash and cash equivalents more than doubled to $73.0 million, bolstered by a $48.6 million equity offering in July 2025 and proceeds from warrant exercises.
• Inventory: The company began capitalizing inventory costs post-FDA approval, resulting in $0.6 million in inventory on the balance sheet, compared to zero in 2024.

Guidance, Outlook, and Risks

Outlook and Strategy:

• Commercialization: CARDAMYST became available in retail pharmacies in Q1 2026. The company targets approximately 500,000 patients in the U.S. for PSVT treatment.
• Pipeline: A Phase 3 study for AFib-RVR is underway, leveraging the PSVT approval pathway. International expansion is pursued via partners (e.g., Corxel in China, EMA submission in Europe).
• Capital Needs: Management expects existing cash and investments to fund operations for at least the next 12 months. However, substantial additional funding will be required for long-term commercialization and development.

Key Risks and Contingencies:

• Profitability: The company anticipates continuing to incur substantial operating losses for the foreseeable future and may never achieve profitability.
• Product Returns: Revenue is subject to risk if product returns from wholesalers exceed the company's reserves.
• Regulatory: Approval in other jurisdictions (EU, China) is not guaranteed. Post-marketing requirements, including pediatric safety trials, are mandated.
• Supply Chain: Reliance on third-party manufacturers for the API and the single-source nasal spray device creates supply risks.
• Subsequent Event: On January 12, 2026, the company closed a sale of royalty interest for $75.0 million, providing a significant cash infusion not reflected in the year-end balance sheet.

Investor Verification Checklist

• Royalty Sale Closure: Verify the receipt of the $75.0 million from the RTW Royalty Purchase Agreement closed in January 2026 and its impact on the Q1 2026 liquidity position.
• Commercial Execution: Monitor early sales data and market penetration rates for CARDAMYST in Q1 and Q2 2026 to validate the 500,000 patient target.
• Product Returns: Review the adequacy of the reserve for product returns as the product scales in the market.
• AFib-RVR Trial Progress: Track enrollment and data readouts for the Phase 3 AFib-RVR study, which is critical for expanding the addressable market.
• Debt Covenants: Review the terms of the $57.2 million Senior Secured Convertible Notes due 2029, specifically regarding interest payment options (cash vs. PIK) and conversion triggers.